Literature DB >> 25714665

Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1.

Jin Ma1, Ting Wang, Rui Guo, Xiaoyan Yang, Jie Yin, Jia Yu, Qiong Xiang, Xia Pan, Huifang Tang, Xiaoyong Lei.   

Abstract

Recent studies have shown that a class of small, functional RNAs, named microRNAs, may regulate multidrug resistance-associated protein 1 (ABCC1). Since ABCC1 is an important efflux transporter responsible for cellular drug disposition, the discovery of microRNAs (miRNA) brings an idea that there may be some other unknown multidrug resistance (MDR) mechanisms exist. Using computational programs, we predicted that the 3'untranslated region (3'UTR) of ABCC1 contains a potential miRNA binding site for miR-133a and also two other for miR-326. These binding sites were confirmed by luciferase reporter assay. ABCC1 mRNA degradation was accelerated dramatically in cells transfected with miR-133a or miR-326 mimics using qRT-PCR, Furthermore, western blot analysis indicated that ABCC1 protein expression was significantly down-regulated in hepatocellular carcinoma cells line HepG2 after transfection with miR-133a or miR-326 mimics, suggesting the involvement of mRNA degradation and protein expression mechanism. The effects of the two miRNAs on adriamycin (ADM) sensitivity to HepG2 cells were determined by MTT assay. Compared with mock transfection, miR-133a or miR-326 mimics transfection sensitized these cells to ADM. These findings for the first time demonstrated that the involvement of miR-133a and miR-326 in MDR is mediated by ABCC1 in hepatocellular carcinoma cell line HepG2 and suggested that miR-133a and miR-326 may be efficient agents for preventing and reversing ADM resistance in cancer cells.

Entities:  

Keywords:  ABCC1; adriamycin; hepatocellular carcinoma; microRNA

Mesh:

Substances:

Year:  2015        PMID: 25714665     DOI: 10.3109/1061186X.2015.1015536

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  21 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

2.  Solanine reverses multidrug resistance in human myelogenous leukemia K562/ADM cells by downregulating MRP1 expression.

Authors:  Ying-Jie Yi; Xiu-Hong Jia; Cong Zhu; Jian-Yong Wang; Jie-Ru Chen; Hong Wang; You-Jie Li
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

3.  miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.

Authors:  Yaomin Li; Yawei Liu; Jing Ren; Shengze Deng; Guozhong Yi; Manlan Guo; Songren Shu; Liang Zhao; Yuping Peng; Songtao Qi
Journal:  J Neurooncol       Date:  2018-06-06       Impact factor: 4.130

Review 4.  microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment.

Authors:  Igor Koturbash; William H Tolleson; Lei Guo; Dianke Yu; Si Chen; Huixiao Hong; William Mattes; Baitang Ning
Journal:  Biomark Med       Date:  2015-10-26       Impact factor: 2.851

5.  Identification of miRNAs contributing to neuroblastoma chemoresistance.

Authors:  Duncan Ayers; Pieter Mestdagh; Tom Van Maerken; Jo Vandesompele
Journal:  Comput Struct Biotechnol J       Date:  2015-04-29       Impact factor: 7.271

6.  MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.

Authors:  Kai-Xuan Sun; Jin-Wen Jiao; Shuo Chen; Bo-Liang Liu; Yang Zhao
Journal:  J Ovarian Res       Date:  2015-12-02       Impact factor: 4.234

7.  Downregulation of eIF4G by microRNA-503 enhances drug sensitivity of MCF-7/ADR cells through suppressing the expression of ABC transport proteins.

Authors:  Xia Pan; Xiaoyan Yang; Jinglei Zang; Si Zhang; Nan Huang; Xinxin Guan; Jianhua Zhang; Zhihui Wang; Xi Li; Xiaoyong Lei
Journal:  Oncol Lett       Date:  2017-04-19       Impact factor: 2.967

8.  miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1.

Authors:  Man Gao; Lingling Miao; Mingxia Liu; Chenggang Li; Cunzhi Yu; Hong Yan; Yongxiang Yin; Yizheng Wang; Xinming Qi; Jin Ren
Journal:  Oncotarget       Date:  2016-09-13

9.  The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma.

Authors:  Yang Zhao; Jing Chen; Wenxin Wei; Xinming Qi; Chunzhu Li; Jin Ren
Journal:  Signal Transduct Target Ther       Date:  2018-01-26

10.  MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma.

Authors:  Wei Zhang; Kai Liu; Songyang Liu; Bai Ji; Yingchao Wang; Yahui Liu
Journal:  Tumour Biol       Date:  2015-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.